Literature DB >> 21684584

Differential expression patterns of CXCR3 variants and corresponding CXC chemokines in clear cell ovarian cancers and endometriosis.

Mitsuko Furuya1, Tomona Yoneyama, Etsuko Miyagi, Reiko Tanaka, Kiyotaka Nagahama, Yohei Miyagi, Yoji Nagashima, Fumiki Hirahara, Yoshiaki Inayama, Ichiro Aoki.   

Abstract

OBJECTIVES: Carcinogenesis of the ovary is often associated with endometriosis. We previously demonstrated that antitumor chemokine receptor CXCR3 was upregulated both in endometriosis and ovarian cancers. Currently, little is known about the roles of CXCR3 variants in these ovarian diseases. In this study, we investigated the expression of CXCR3 variants and their corresponding ligands in endometriosis and ovarian cancers.
METHODS: The expression patterns of CXCR3 variants (CXCR3A, CXCR3B and CXCR3-alt) and their corresponding ligands were investigated by quantitative RT-PCR, Western blot and in situ hybridization in normal ovaries (n=16), endometriosis (n=12), and clear cell ovarian cancers (n=22) including endometriosis-coexisting cases (n=11).
RESULTS: Sequence analysis of purified RT-PCR products confirmed the presence of three CXCR3 variants in human ovaries. Quantitative RT-PCR analysis revealed differential expression patterns of these variants depending on conditions. CXCR3A was upregulated both in endometriosis and cancers. On the other hand, CXCR3-alt was upregulated and CXCR3B was downregulated in cancers compared with endometriosis. The corresponding ligand CXCL11 was upregulated only in the cancers with elevated CXCR3-alt. Another ligand CXCL4 was downregulated in the cancers with suppressed CXCR3B. In situ hybridization demonstrated preferential expression of CXCR3A in cancer cells and infiltrating lymphocytes. CXCR3B and CXCR3-alt were detectable mainly in microvessels.
CONCLUSIONS: Collective data suggest that differential expression patterns of CXC chemokines and CXCR3 variants are involved in specific inflammatory microenvironment of ovarian cancers. Altered balance of CXCR3 variants may become helpful information for better understanding of the pathogenesis of ovarian cancers arising from endometriosis.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21684584     DOI: 10.1016/j.ygyno.2011.05.034

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  14 in total

1.  Potential role of CXCR3 in proliferation and invasion of prostate cancer cells.

Authors:  Daqing Shen; Xianxiang Cao
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

Review 2.  CXCR3 in carcinoma progression.

Authors:  Bo Ma; Ahmad Khazali; Alan Wells
Journal:  Histol Histopathol       Date:  2015-02-09       Impact factor: 2.303

Review 3.  Immunologic factors involved in the malignant transformation of endometriosis to endometriosis-associated ovarian carcinoma.

Authors:  S Leenen; M Hermens; P J de Vos van Steenwijk; R L M Bekkers; E M G van Esch
Journal:  Cancer Immunol Immunother       Date:  2021-01-07       Impact factor: 6.968

4.  Chemokine receptor CXCR3 deficiency exacerbates murine autoimmune cholangitis by promoting pathogenic CD8+ T cell activation.

Authors:  Hong-Di Ma; Wen-Tao Ma; Qing-Zhi Liu; Zhi-Bin Zhao; Mu-Zi-Ying Liu; Koichi Tsuneyama; Jin-Ming Gao; William M Ridgway; Aftab A Ansari; M Eric Gershwin; Yun-Yun Fei; Zhe-Xiong Lian
Journal:  J Autoimmun       Date:  2017-01-24       Impact factor: 7.094

Review 5.  Molecular pathways: hepatitis C virus, CXCL10, and the inflammatory road to liver cancer.

Authors:  Jessica Brownell; Stephen J Polyak
Journal:  Clin Cancer Res       Date:  2013-01-15       Impact factor: 12.531

Review 6.  Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12.

Authors:  Anup Kumar Singh; Rakesh Kumar Arya; Arun Kumar Trivedi; Sabyasachi Sanyal; Rathindranath Baral; Olivier Dormond; David M Briscoe; Dipak Datta
Journal:  Cytokine Growth Factor Rev       Date:  2012-09-16       Impact factor: 7.638

7.  Impaired CXCL4 expression in tumor-associated macrophages (TAMs) of ovarian cancers arising in endometriosis.

Authors:  Mitsuko Furuya; Reiko Tanaka; Etsuko Miyagi; Daisuke Kami; Kiyotaka Nagahama; Yohei Miyagi; Yoji Nagashima; Fumiki Hirahara; Yoshiaki Inayama; Ichiro Aoki
Journal:  Cancer Biol Ther       Date:  2012-06-01       Impact factor: 4.742

8.  Ovarian cancer stroma: pathophysiology and the roles in cancer development.

Authors:  Mitsuko Furuya
Journal:  Cancers (Basel)       Date:  2012-07-18       Impact factor: 6.639

9.  Aberrant proliferation in CXCR7+ endothelial cells via degradation of the retinoblastoma protein.

Authors:  Jennifer E Totonchy; Jessica M Osborn; Sara Botto; Lisa Clepper; Ashlee V Moses
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

10.  Plasma endothelial protein C receptor influences innate immune response in ovarian cancer by decreasing the population of natural killer and TH17 helper cells.

Authors:  Dalel Azzazene; Hamda Al Thawadi; Halema Al Farsi; Samaher Besbes; Caroline Geyl; Shahsoltan Mirshahi; Julia Pardo; Anne Marie Faussat; Soria Jeannette; Amu Therwath; Eric Pujade-Lauraine; Massoud Mirshahi
Journal:  Int J Oncol       Date:  2013-07-18       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.